These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15579757)

  • 1. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.
    Smith SA; Porter LE; Biswas N; Freed MI
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6048-53. PubMed ID: 15579757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB; Al Majali K; Bailey CJ; Betteridge DJ
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
    Prigeon RL; Jacobson RK; Porte D; Kahn SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus.
    Saad MF; Kahn SE; Nelson RG; Pettitt DJ; Knowler WC; Schwartz MW; Kowalyk S; Bennett PH; Porte D
    J Clin Endocrinol Metab; 1990 May; 70(5):1247-53. PubMed ID: 2186054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
    Røder ME; Porte D; Schwartz RS; Kahn SE
    J Clin Endocrinol Metab; 1998 Feb; 83(2):604-8. PubMed ID: 9467581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
    Pfützner A; Schöndorf T; Seidel D; Winkler K; Matthaei S; Hamann A; Forst T
    Metabolism; 2006 Jan; 55(1):20-5. PubMed ID: 16324915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
    Hanefeld M; Patwardhan R; Jones NP;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):13-23. PubMed ID: 17174222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.
    Ovalle F; Bell DS
    Diabetes Care; 2004 Nov; 27(11):2585-9. PubMed ID: 15504990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
    Ghanim H; Dhindsa S; Aljada A; Chaudhuri A; Viswanathan P; Dandona P
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3553-8. PubMed ID: 16804037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM.
    Kahn SE; Halban PA
    Diabetes; 1997 Nov; 46(11):1725-32. PubMed ID: 9356018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
    Prigeon RL; Kahn SE; Porte D
    J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
    Wallace TM; Levy JC; Matthews DR
    Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
    Ohkura T; Inoue K; Fujioka Y; Nakanishi R; Shiochi H; Sumi K; Yamamoto N; Matsuzawa K; Izawa S; Ohkura H; Kato M; Yamamoto K; Taniguchi S
    BMC Res Notes; 2013 Nov; 6():453. PubMed ID: 24215809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity--clinical research center study.
    Kahn SE; Leonetti DL; Prigeon RL; Boyko EJ; Bergstrom RW; Fujimoto WY
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1399-406. PubMed ID: 7714116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
    Juhl CB; Hollingdal M; Pørksen N; Prange A; Lönnqvist F; Schmitz O
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3794-800. PubMed ID: 12915671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.